The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem
Jeff Keyser tells us about trying to help patients recover from surgeries more efficiently and the phase 2 data that led to Renibus' breakthrough therapy designation.
Brought to you by:
